MORRIS PLAINS, N.J., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or “the Company”) today commenced mailing of a letter to stockholders in connection with its upcoming 2016 Annual Meeting of Stockholders to be held on February 16, 2017. The letter urges Immunomedics stockholders to vote FOR all seven of the Company’s director nominees – Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester, Dr. David M. Goldenberg, Brian A. Markison, Bob Oliver and Cynthia L. Sullivan – at the upcoming Annual Meeting.
The full text of the letter follows:
PROTECT YOUR INVESTMENT IN IMMUNOMEDICS BY VOTING “FOR” THE IMMUNOMEDICS NOMINEES ON THE WHITE PROXY CARD TODAY!
February 2, 2017
Dear Fellow Immunomedics Stockholders,
At the Immunomedics Annual Stockholders Meeting on February 16, 2017, you, the owners of Immunomedics, will need to make a choice between continuing the value-enhancing actions fully underway by your new Immunomedics Board of Directors OR handing control of the Company to venBio. venBio has made it clear they will stop the broad strategic process underway, and in likely destabilizing the Company, they would delay initiation of the Company’s Phase 3 trial for IMMU-132 in TNBC patients, including a postponement in filing for accelerated FDA approval, which would destroy near-term value. Furthermore, venBio is offering no premium to stockholders for this effective control of your Company.
YOUR NEW BOARD IS ACUTELY FOCUSED ON EXPEDITIOUSLY
MAXIMIZING STOCKHOLDER VALUE
Your new Board includes highly qualified and independent members Jason Aryeh, an active fund manager who is a highly regarded and proven shareholder advocate, along with Dr. Geoffrey Cox, Robert Forrester, Brian Markison and Bob Oliver, who collectively have significant experience assembling drug applications and manufacturing complex biologic therapeutics at commercial scale.
Your new Board is leveraging its significant, relevant expertise on behalf of all stockholders. We are highly involved in the process underway at Immunomedics to maximize the value of IMMU-132. Your new Board’s deep engagement and decades of relevant experience commercializing and manufacturing drugs at development phase and global conglomerate companies are facilitating a smooth process with regard to chemistry, manufacturing and controls (CMC).
Our process is supported by independent experts who have conducted a full commercial assessment and an independent audit of the Company’s Phase 3 and commercial manufacturing facilities, processes and other relevant regulatory areas.
YOUR NEW BOARD IS OVERSEEING A CREDIBLE PLAN;
WE BELIEVE VENBIO OFFERS NO PLAN OTHER THAN ONE THAT WOULD CAUSE DELAY AND PUT YOUR INVESTMENT AT RISK
Despite the misleading statements, inaccuracies and mischaracterizations that venBio has been communicating to Immunomedics stockholders, your new Board continues to make real progress against a credible, tangible and achievable plan - and is on track to achieve each of its articulated and critical near-term value-enhancing milestones.
We believe venBio has made clear that its only “plan” is “making a plan” at an undetermined point in the future. Given venBio’s unwillingness to work together and avoid a proxy contest, we believe it is important for stockholders to be able to compare the two plans for themselves:
|venBio’s “Plan”||The Immunomedics Plan Underway by Your New Board|
|“Evaluate strategic options to advance ‘132 as rapidly as possible…”||–||Your new Board is engaged in an ongoing robust strategic process being led by an outside financial advisor, Greenhill & Co., who is reporting directly to your newly formed Transaction Committee, composed exclusively of your new Independent Directors.|
|“Implement CEO succession plan…”||–||Your new Directors have already implemented a responsible succession plan for the CEO and Chairman, including having announced and already initiated a formal search for a new CEO and a succession plan for the Chairmanship.|
|“Evaluate and identify key talent to focus on IMMU-132”||–||Your new Board includes four highly respected, ideally qualified, complementary and completely independent Directors who collectively bring over 125 years of pharmaceutical and life sciences experience.|
|“Evaluate key operating processes – clinical, manufacturing, regulatory, commercial, etc.”||–||Independent third-party experts have already conducted a full commercial assessment of the U.S. and European market opportunities for IMMU-132, as well as an independent audit of Phase 3 and commercial manufacturing facilities, processes, and other relevant manufacturing and regulatory areas.|
We believe the facts demonstrate it is clear that the Immunomedics Board is overseeing a real, credible and thoughtful plan that is well underway to deliver value to you, our valued stockholders. venBio’s lack of a concrete plan – and the time that it will take for them to develop a detailed and credible plan – will cause a delay in the actions your new Board of Directors has underway and, therefore, cause dramatic and unnecessary value destruction. Minimizing near-term disruption at the Company will better enable the new Board to create maximum value for all stockholders.
THE FUTURE OF YOUR INVESTMENT DEPENDS ON YOUR VOTE
VOTE THE WHITE PROXY CARD TODAY!
We urge stockholders to vote FOR the Immunomedics nominees: Jason Aryeh, Dr. Geoffrey Cox, Robert Forrester, Dr. David M. Goldenberg, Brian A. Markison, Bob Oliver and Cynthia L. Sullivan. The new Immunomedics Board is acting in the interests of all stockholders and brings the ideal combination of diversity, existing product knowledge, relevant oncology expertise, broad M&A experience and a history of stockholder advocacy needed to successfully execute upon the actions we have underway and deliver upon the full value potential of your investment.
Protect the value of your investment in Immunomedics by using the enclosed WHITE proxy card to vote “FOR” each of Immunomedics seven nominees TODAY by telephone, by Internet, or by signing and dating the WHITE proxy card and returning it in the postage-paid envelope provided. No matter how few shares you own, it is important that all stockholders have their voices heard. If you have previously voted on venBio’s proxy card you can revoke that vote by submitting a later dated WHITE proxy card. Only your latest dated card will be counted at the Annual Meeting.
On behalf of your Board of Directors, we thank you for your continued support.
Your new Board of Directors
|/s/ Dr. David M. Goldenberg |
Dr. David M. Goldenberg, Chairman
/s/ Robert Forrester
Robert Forrester, Independent Director
/s/ Cynthia L. Sullivan
Cynthia L. Sullivan, Director
|/s/ Jason Aryeh |
Jason Aryeh, Vice Chairman
/s/ Dr. Geoff Cox
Dr. Geoff Cox, Independent Director
|/s/ Brian A. Markison |
Brian A. Markison, Lead Independent Director
/s/ Bob Oliver
Bob Oliver, Independent Director
If you have any questions or require any assistance with voting your shares,
please contact the Company’s proxy solicitor listed below:
Vinson & Elkins L.L.P. and DLA Piper LLP (US) are serving as legal advisors and Greenhill & Co., LLC is serving as financial advisor to Immunomedics.
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 306 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.
Important Additional Information
Immunomedics, Inc. (the “Company”), its directors and certain of its executive officers will be deemed to be participants in the solicitation of proxies from Company stockholders in connection with the matters to be considered at the Company’s 2016 Annual Meeting. The Company has filed a definitive proxy statement and form of WHITE proxy card with the U.S. Securities and Exchange Commission (the “SEC”) in connection with any such solicitation of proxies from Company stockholders. COMPANY STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS AND SUPPLEMENTS), THE ACCOMPANYING WHITE PROXY CARD AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY FILES WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Information regarding the identity of participants, and their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement and other materials filed by the Company with the SEC. Stockholders will be able to obtain the proxy statement, any amendments or supplements to the proxy statement and other documents filed by the Company with the SEC for no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at www.immunomedics.com, by writing to Immunomedics, Inc. at 300 The American Road, Morris Plains, New Jersey 07950, or by calling the Company’s proxy solicitor, or by calling Dr. Chau Cheng, Senior Director, Investor Relations & Corporate Secretary, (973) 605-8200, extension 123.
This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs), regulatory applications and related timelines, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, the Company’s dependence on business collaborations or availability of required financing from capital markets, or other sources on acceptable terms, if at all, in order to further develop our products and finance our operations, new product development (including clinical trials outcome and regulatory requirements/actions), the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and the Company’s ability to repay its outstanding indebtedness, if and when required, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.
For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123 email@example.com Media Dan Katcher / Ed Trissel / Nick Lamplough Joele Frank, Wilkinson Brimmer Katcher (212) 355-4449 Investors Dan Burch/Bob Marese MacKenzie Partners, Inc. firstname.lastname@example.org / email@example.com (212) 929-5500